Evaluation of Sex-Specific Incidence of Melanoma.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 05 2020
Historique:
pubmed: 27 3 2020
medline: 30 12 2020
entrez: 27 3 2020
Statut: ppublish

Résumé

Men and women develop melanoma at different rates on different body sites, with variation across countries, but explanations for these disparities remain elusive. To test whether observed differences in melanoma incidence between men and women vary by population, age, or anatomic site. Cross-sectional analysis of sex- and site-specific temporal trends in melanoma incidence over 3 decades was conducted for men and women diagnosed with invasive melanoma in the US (limited to white race), Canada, Australia, New Zealand, the UK, Sweden, Norway, and Denmark. Using cancer registry data, male to female incidence rate ratios (IRRs) were calculated overall and by anatomic site, and Joinpoint regression models were used to estimate the annual percentage rate changes in sex- and site-specific incidence in each population. Incidence rates were standardized to the US 2000 population. Data on the incidence between January 1, 1982, and December 31, 2015, were obtained; analysis was conducted from March 1 to October 15, 2019. Male to female IRRs and annual percentage change in rates. Total melanoma incidence was higher in men than women in US individuals (limited to white race), Canada, Australia, and New Zealand, but not in Denmark, the UK, Norway, and Sweden. In all populations, men had higher rates of melanoma of the head and neck and trunk than women (male to female IRR >1), but lower melanoma rates on the lower limbs (ie, male to female IRR approximately 0.5). The male to female IRR increased log linearly with age, with excess melanomas in women younger than 45 years in all populations (eg, IRR for 20-24 y age group, 0.3 in Denmark and 0.7 in Australia), and excess melanomas in men older than 69 years (eg, IRR for 70-74 y age group, 1.1 in Denmark and 2.1 in the US white population). The age at which the melanoma incidence in men exceeded the melanoma incidence in women differed by population, being achieved the earliest in Australia (45-49 years) and latest in Denmark (65-69 years). In predominantly fair-skinned populations, melanoma incidence appears to differ systematically and consistently between men and women by age and anatomic site.

Identifiants

pubmed: 32211827
pii: 2763192
doi: 10.1001/jamadermatol.2020.0470
pmc: PMC7097866
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

553-560

Commentaires et corrections

Type : ErratumIn

Références

Br J Dermatol. 2008 Apr;158(4):766-72
pubmed: 18241261
J Natl Cancer Inst. 2020 May 1;112(5):533-539
pubmed: 31346623
J Natl Cancer Inst. 2003 Jun 4;95(11):806-12
pubmed: 12783935
J Invest Dermatol. 1965 Oct;45(4):295-8
pubmed: 5320054
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2296-302
pubmed: 25146089
Int J Environ Res Public Health. 2019 Mar 13;16(6):
pubmed: 30871230
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2003-5
pubmed: 15598754
Int J Epidemiol. 2000 Jun;29(3):416-23
pubmed: 10869312
J Am Acad Dermatol. 2017 Mar;76(3):499-505.e3
pubmed: 28413057
Br Med J. 1954 May 1;1(4869):1016-7
pubmed: 13149891
Arch Dermatol. 1990 Apr;126(4):466-71
pubmed: 2321992
J Invest Dermatol. 2009 Jul;129(7):1666-74
pubmed: 19131946
J Am Acad Dermatol. 2008 Dec;59(6):1081-5
pubmed: 19022107
Arch Dermatol. 1999 Jan;135(1):47-52
pubmed: 9923780
J Invest Dermatol. 1979 Aug;73(2):141-3
pubmed: 88488
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1241-4
pubmed: 15894679
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
J Am Acad Dermatol. 2003 Mar;48(3):367-75
pubmed: 12637916
Int J Epidemiol. 2009 Jun;38(3):814-30
pubmed: 19359257
J Invest Dermatol. 2019 Jun;139(6):1392-1395
pubmed: 30578821
Pigment Cell Melanoma Res. 2020 Mar;33(2):326-333
pubmed: 31403758
Cancer. 2009 Sep 15;115(18):4176-85
pubmed: 19536874

Auteurs

Catherine M Olsen (CM)

Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

John F Thompson (JF)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.

Nirmala Pandeya (N)

Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
The University of Queensland School of Public Health, Brisbane, Queensland, Australia.

David C Whiteman (DC)

Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH